July 8, 2020 / 9:43 AM / a month ago

Panacea Biotec sees production of 1 bln doses of COVID-19 vaccine candidate in 2022

BENGALURU, July 8 (Reuters) - Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.

The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement.

Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Krishna Chandra Eluri

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below